Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […]

Related Keywords

United States , America , Andrew Cheng , Catriona Yale , Nasdaq , Orion Capital Management , Russell Investments Group Ltd , Headlands Technologies , Canaccord Genuity Group , Akero Therapeutics Inc , Akero Therapeutics , Get Free Report , Investments Group , Therapeutics Stock Down , Get Free , Akero Therapeutics Daily ,